Status:
COMPLETED
Escitalopram for the Treatment of Self-Injurious Skin Picking
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
Forest Laboratories
Conditions:
Impulse Control Disorders
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking.
Detailed Description
Purpose: Self-injurious skin picking is a problem documented to occur in 2 % of dermatology patients (Gupta, Gupta and Haberman, 1986) , and approximately 4% of the general population (Keuthen et al.,...
Eligibility Criteria
Inclusion
- Repetitive skin picking resulting in noticeable tissue damage and associated emotional distress and/or functional impairment.
- Age 18-65 years old.
- Duration of skin picking symptoms ≥ 6 months.
- MGH Skin Picking Scale score ≥ 10.
- Written informed consent.
- Females of childbearing potential must have a negative serum or urinary beta-HCG test and be willing to use acceptable methods of birth control during study tenure.
Exclusion
- Pregnant women or females of childbearing potential who do not consent to use of a medically acceptable method of contraception.
- Women who are breastfeeding.
- Subjects who pose a serious suicidal or homicidal risk in the judgment of study investigators.
- Serious or unstable medical illness including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease.
- Subjects with a dermatologic disorder that causes pruritis.
- Patients on anticoagulant therapy.
- History of seizure disorder.
- Comorbid bipolar disorder, psychosis, organic mental disorder, borderline personality disorder or developmental disorder. Subjects with obsessive compulsive disorder (with primary symptoms other than compulsive skin picking).
- History of substance dependence. If there is a history of substance abuse, subjects should be in remission for ≥ 6 months.
- Current treatment with cognitive behavioral therapy for skin picking.
- Current use of another SSRI medication.
- Other medications for medical disorders that might interfere with escitalopram.
- Current major depression or prescribed an antidepressant for major depression within the past 12 months.
- More than 1 adequate trial (at least 10 weeks at maximally tolerated dose) with another prior SSRI.
Key Trial Info
Start Date :
September 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00115011
Start Date
September 1 2002
End Date
November 1 2005
Last Update
May 20 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114